Leslie Citrome

Summary

Publications

  1. pmc Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Ther Clin Risk Manag 9:235-45. 2013
  2. doi Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
    Leslie Citrome
    11 Medical Park Drive, Ste 106, Pomona, NY 10970
    J Clin Psychiatry 75:21-6. 2014
  3. ncbi Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics
    Leslie Citrome
    11 Medical Park Dr, Ste 106, Pomona, NY 10970
    J Clin Psychiatry 74:1199-206. 2013
  4. doi Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA Electronic address
    J Affect Disord 155:20-7. 2014
  5. ncbi Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York Electronic address
    Clin Ther 35:1867-75. 2013
  6. ncbi A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    CNS Drugs 27:879-911. 2013
  7. doi New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Expert Rev Neurother 13:767-83. 2013
  8. ncbi When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    L Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 67:407-11. 2013
  9. doi Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy
    Leslie Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 30:114-26. 2013
  10. doi Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy
    Leslie Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 30:102-13. 2013

Detail Information

Publications57

  1. pmc Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Ther Clin Risk Manag 9:235-45. 2013
    ....
  2. doi Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
    Leslie Citrome
    11 Medical Park Drive, Ste 106, Pomona, NY 10970
    J Clin Psychiatry 75:21-6. 2014
    ....
  3. ncbi Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics
    Leslie Citrome
    11 Medical Park Dr, Ste 106, Pomona, NY 10970
    J Clin Psychiatry 74:1199-206. 2013
    ..To examine the risk of cardiovascular outcomes and diabetes mellitus in patients prescribed second-generation antipsychotics...
  4. doi Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA Electronic address
    J Affect Disord 155:20-7. 2014
    ..harms)...
  5. ncbi Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York Electronic address
    Clin Ther 35:1867-75. 2013
    ..Atypical antipsychotics are indicated for specific psychiatric conditions; however, they are frequently used for US Food and Drug Administration-nonapproved indications...
  6. ncbi A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    CNS Drugs 27:879-911. 2013
    ....
  7. doi New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Expert Rev Neurother 13:767-83. 2013
    ..After a review of the evidence base, guidance is offered on the appropriate selection among the long-acting injectable formulations of both first and second-generation antipsychotics. ..
  8. ncbi When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    L Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 67:407-11. 2013
    ..Additional considerations in interpreting NNT are discussed, including the importance of defining acceptable response, adverse outcomes of interest, the effect of time, and the importance of individual baseline characteristics...
  9. doi Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy
    Leslie Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 30:114-26. 2013
    ..Cariprazine differs from aripiprazole in terms of dopamine D3 receptor selectivity. Further studies would be helpful to discern the distinguishing features of cariprazine from other second-generation antipsychotics...
  10. doi Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy
    Leslie Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 30:102-13. 2013
    ..Cariprazine differs from aripiprazole in terms of dopamine D3 receptor selectivity. Further studies would be helpful to discern the distinguishing features of cariprazine from other antimanic agents...
  11. doi Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Expert Opin Drug Metab Toxicol 9:193-206. 2013
    ..Cariprazine is an atypical antipsychotic in clinical development for the treatment of schizophrenia and bipolar mania/mixed episodes...
  12. doi Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials
    Leslie Citrome
    New York Medical College, Valhalla, New York, USA
    Hum Psychopharmacol 27:24-32. 2012
    ....
  13. doi Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Clin Schizophr Relat Psychoses 6:76-85. 2012
    ..To describe the efficacy, safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat (NNT) and number needed to harm (NNH)...
  14. doi Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Int Clin Psychopharmacol 27:165-76. 2012
    ..All-cause discontinuation rates were higher for lurasidone versus risperidone. Long-term treatment with lurasidone was generally well tolerated in this study, with minimal effects on weight and metabolic outcomes...
  15. doi Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Psychiatry 74:170-9. 2013
    ..To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies...
  16. doi Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Schizophr Res 115:115-20. 2009
    ..The purpose of this study is to evaluate the relationship between maximum dose of ziprasidone and time to discontinuation in the treatment of schizophrenia/schizoaffective disorder and bipolar disorder in clinical practice...
  17. doi Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Clin Drug Investig 31:455-82. 2011
    ..Long-term weight management programmes have been shown to reduce weight gain in some patients...
  18. doi Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study
    Karen A Nolan
    Clinical Research Division, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, 10962, USA
    Psychiatr Q 80:167-72. 2009
    ..Responses to aggressive events do not take causes into account. It is possible that consideration of the reasons for the aggressive behavior might yield more targeted interventions...
  19. ncbi Do guidelines for severe mental illness promote physical health and well-being?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:102-9. 2005
    ....
  20. doi Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis
    Leslie Citrome
    New York University School of Medicine, New York, NY, USA
    Schizophr Res 131:75-81. 2011
    ..We conducted a 5-factor analysis for evaluating the efficacy of iloperidone vs. placebo across these different domains in the treatment of schizophrenia...
  21. doi Iloperidone: a clinical overview
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    J Clin Psychiatry 72:19-23. 2011
    ..Iloperidone may be best suited for patients who are sensitive to akathisia or who are unable to tolerate the sedation and weight gain that can occur more frequently with other antipsychotics...
  22. doi Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    CNS Spectr 17:1-9. 2012
    ..We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results...
  23. ncbi Metabolic syndrome and cardiovascular disease
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:84-93. 2005
    ..Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate...
  24. doi Drug safety evaluation of ziprasidone
    Leslie Citrome
    New York University School of Medicine, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Drug Saf 10:437-48. 2011
    ..The purpose of this review is to assess the overall safety profile of ziprasidone, including its risk for prolonging the electrocardiogram (ECG) QT interval...
  25. doi Pharmacological management of acute and persistent aggression in forensic psychiatry settings
    Leslie Citrome
    New York Medical College, Department of Psychiatry and Behavioral Sciences, Valhalla, USA
    CNS Drugs 25:1009-21. 2011
    ..Mood stabilizers such as valproate may be helpful in instances of poor impulsivity and personality disorders. Other agents that have been successfully used include β-adrenoceptor antagonists (β-blockers) and antidepressants...
  26. pmc Pathways to aggression in schizophrenia affect results of treatment
    Jan Volavka
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Schizophr Bull 37:921-9. 2011
    ..Treatment adherence has a crucial role in the prevention of aggressive behavior in schizophrenia patients...
  27. doi Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, New York, NY, USA
    Postgrad Med 123:153-62. 2011
    ..Longer-term and naturalistic studies will be helpful in evaluating these agents and their role in the psychiatric armamentarium...
  28. ncbi Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response
    Jean Pierre Lindenmayer
    New York University School of Medicine, New York, N Y 10035, USA
    J Clin Psychiatry 70:990-6. 2009
    ..To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence...
  29. ncbi The effectiveness criterion: balancing efficacy against the risks of weight gain
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:12-7. 2007
    ..Predictors of weight gain for olanzapine are reviewed for schizophrenia and bipolar disorder, as is a monitoring plan applicable for all patients receiving antipsychotic therapy...
  30. ncbi Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials
    William M Greenberg
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    CNS Drug Rev 13:137-77. 2007
    ....
  31. ncbi Metabolic issues in patients with severe mental illness
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    South Med J 98:714-20. 2005
    ..Collaborative treatment between a psychiatrist and an endocrinologist is encouraged. The primary care physician may be required to fulfill both roles...
  32. doi "Stat" medication administration predicts hospital discharge
    Ari Jaffe
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA
    Psychiatr Q 80:65-73. 2009
    ..This study describes the use of "stat" medications for inpatients in a large state psychiatric hospital system, and examines the relationship between receipt of a "stat" for agitation and subsequent hospital discharge...
  33. ncbi Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  34. doi A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities
    Jean Pierre Lindenmayer
    New York University School of Medicine, 600 East 125th Street, New York, NY 10035, USA
    Schizophr Res 147:241-52. 2013
    ....
  35. ncbi Latest therapies for bipolar disorder. Looking beyond lithium
    Joseph F Goldberg
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    Postgrad Med 117:25-6, 29-32, 35-6. 2005
    ..Maintenance treatments that have received FDA approval include olanzapine and lamotrigine. Off-label use of adjunctive medications may be required to target residual symptoms...
  36. ncbi Toward convergence in the medication treatment of bipolar disorder and schizophrenia
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Harv Rev Psychiatry 13:28-42. 2005
    ....
  37. doi A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Psychopharmacology Research Program, New York, NY, USA
    J Clin Psychopharmacol 31:160-8. 2011
    ..In conclusion, quetiapine at 1200 mg/d, although reasonably tolerated, did not confer any advantages over quetiapine at 600 mg/d among patients who had failed to demonstrate an adequate response to a prospective 4-week trial of 600 mg/d...
  38. doi Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Expert Opin Drug Metab Toxicol 8:873-88. 2012
    ..It is also approved for the treatment of adults with schizoaffective disorder, both as a monotherapy and as adjunctive therapy to mood stabilizers and/or antidepressants. Paliperidone is the active metabolite of risperidone...
  39. doi Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 4:251-7. 2011
    ..Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval...
  40. doi Olanzapine-fluoxetine combination for the treatment of bipolar depression
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, Valhalla, NY 10970, USA
    Expert Opin Pharmacother 12:2751-8. 2011
    ..Olanzapine-fluoxetine combination is one of only two products currently approved by the US FDA for the acute treatment of depressive episodes associated with bipolar disorder...
  41. ncbi Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA Electronic address
    J Affect Disord 151:409-17. 2013
    ..This is a quantitative review of existing studies of transdermal selegiline for major depressive disorder...
  42. ncbi The many faces of bipolar disorder. How to tell them apart
    Leslie Citrome
    New York University School of Medicine, New York, USA
    Postgrad Med 117:15-6, 19-23. 2005
    ..Effective pharmacotherapy and maintenance monitoring are critical in order to minimize the risk of relapse and associated disability, morbidity, and mortality...
  43. pmc Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot
    Leslie Citrome
    Dr Citrome is with the Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York Drs Kalsekar, Guo, and Hebden are with Bristol Myers Squibb, Plainsboro, New Jersey Dr Forbes is with Otsuka Pharmaceutical Development and Commercialization, Princeton, New Jersey
    Innov Clin Neurosci 9:17-8. 2012
    ..These findings indicate that from the perspective of "practice-based evidence," providers see value in combination therapy...
  44. ncbi The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    J Clin Psychiatry 68:331-2. 2007
  45. ncbi Introduction: weighing the evidence: weight management insights for treating major mental illness
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:4. 2007
  46. doi Lurasidone in schizophrenia: new information about dosage and place in therapy
    Leslie Citrome
    Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY 10970, USA
    Adv Ther 29:815-25. 2012
    ..Additional studies are desirable to directly compare and contrast lurasidone's efficacy with other antipsychotic agents...
  47. doi Lurasidone for schizophrenia: what's different?
    Joshua T Kantrowitz
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Expert Rev Neurother 12:265-73. 2012
    ..It is recommended that lurasidone be administered once daily with at least 350 calories of food. Additional studies are desirable to directly compare and contrast lurasidone with other antipsychotic agents...
  48. doi Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, New York, USA
    Expert Rev Neurother 9:55-71. 2009
    ....
  49. ncbi Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus
    Leslie Citrome
    New York University School of Medicine, NY, USA
    Int J Neuropsychopharmacol 8:147-51. 2005
  50. doi A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1545-73. 2012
    ..Meta-analyses can overcome many of the limitations of individual studies, namely the power to detect differences, and help resolve the results of inconsistent studies...
  51. doi On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1599-613. 2012
    ..The product label is commonly used as an authoritative source for drug information, especially for new medications that have a limited published evidence base. Key elements of the product label are descriptions of safety and tolerability...
  52. ncbi The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:163-4. 2007
  53. doi GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications
    Joshua Kantrowitz
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    CNS Drugs 23:681-91. 2009
    ..Further study is needed...
  54. doi Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion
    Leslie Citrome
    New York University School of Medicine, New York City, NY, USA
    Expert Opin Drug Metab Toxicol 6:1551-64. 2010
    ..Iloperidone is a newly commercialized second-generation (atypical) antipsychotic approved for the acute treatment of schizophrenia in adults...
  55. ncbi Optimal dosing of atypical antipsychotics in adults: a review of the current evidence
    Leslie Citrome
    Department of Psychiatry, New York University, New York, N Y, USA
    Harv Rev Psychiatry 10:280-91. 2002
    ....
  56. doi Stimulant-induced trichotillomania
    Gareen Hamalian
    Department of Psychiatry, New York University School of Medicine, New York City, New York, USA
    Subst Abus 31:68-70. 2010
    ..Given the increase in exposure of prescription amphetamines among adults, further study into the association between stimulants and adverse events such as trichotillomania is needed...
  57. pmc Paliperidone: the evidence of its therapeutic value in schizophrenia
    Joshua Kantrowitz
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    Core Evid 2:261-71. 2008
    ..It will become even harder to justify when risperidone becomes available as a less expensive generic medication...